AstraZeneca developed Rilvegostomig using Compugen's antibody, and Gilead licensed GS-0321 from Compugen.
5 reports, 1 independent
Updated Sep 8
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca developed Rilvegostomig using Compugen's antibody, and Gilead licensed GS-0321 from Compugen.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AstraZeneca and Gilead secure deals with Compugen for drug development and licensing.1 source
Compugen Ltd. is based in Israel and Anat Cohen-Dayag serves as its CEO.1 source
Keep exploring
The entities involved
-
Compugen Ltd.
publicly traded Israeli drug discovery company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
-
Gilead
ancient Israelite geographical location in modern day Jordan
Nothing else this week.
Coverage
Newest first; wire copies grouped- PR NewswireCompugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference HOLON, Israel, Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer imm
- PR NewswireCompugen Reports Second Quarter 2025 Results First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled an
- PR NewswireCompugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunother
- PR NewswireCompugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in